• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

弥漫性大B细胞淋巴瘤的靶向治疗和免疫治疗

Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma.

作者信息

Chaudhari Jahnavi, Shah Nikesh N

机构信息

Department of Internal Medicine, HCA Florida Oak Hill Hospital, Brooksville, FL 34613, USA.

USF Health Morsani College of Medicine, Tampa, FL 33602, USA.

出版信息

Cancers (Basel). 2025 Jul 30;17(15):2517. doi: 10.3390/cancers17152517.

DOI:10.3390/cancers17152517
PMID:40805213
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12345741/
Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma (NHL) [...].

摘要

弥漫性大B细胞淋巴瘤（DLBCL）是最常见的侵袭性非霍奇金淋巴瘤（NHL）[...]。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4999/12345741/30db1235fa23/cancers-17-02517-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4999/12345741/30db1235fa23/cancers-17-02517-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4999/12345741/30db1235fa23/cancers-17-02517-g001.jpg

相似文献

1
Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma.弥漫性大B细胞淋巴瘤的靶向治疗和免疫治疗
Cancers (Basel). 2025 Jul 30;17(15):2517. doi: 10.3390/cancers17152517.
2
Bispecific Antibodies and Antibody-Drug Conjugates in Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma, Focusing on Diffuse Large B-Cell Lymphoma.双特异性抗体和抗体药物偶联物在复发/难治性侵袭性非霍奇金淋巴瘤中的应用，重点关注弥漫性大B细胞淋巴瘤
Cancers (Basel). 2025 Jul 26;17(15):2479. doi: 10.3390/cancers17152479.
3
Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma.Loncastuximab tesirine 用于治疗复发或难治性弥漫性大 B 细胞淋巴瘤。
Expert Opin Biol Ther. 2021 Nov;21(11):1373-1381. doi: 10.1080/14712598.2021.1973998. Epub 2021 Sep 10.
4
Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody.复发难治性弥漫性大B细胞淋巴瘤的治疗：双特异性单克隆抗体格菲妥单抗在治疗中的地位初步评估
Cureus. 2022 Dec 31;14(12):e33169. doi: 10.7759/cureus.33169. eCollection 2022 Dec.
5
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.抗 CD79B 抗体药物偶联物 polatuzumab vedotin 在复发或难治性 B 细胞非霍奇金淋巴瘤和慢性淋巴细胞白血病中的安全性和活性：一项 1 期研究。
Lancet Oncol. 2015 Jun;16(6):704-15. doi: 10.1016/S1470-2045(15)70128-2. Epub 2015 Apr 27.
6
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: drug profile and expert opinion on the prevention and management of adverse events.Loncastuximab tesirine治疗复发/难治性弥漫性大B细胞淋巴瘤：药物概况及不良事件预防与管理的专家意见
Leuk Lymphoma. 2025 Jun 30:1-13. doi: 10.1080/10428194.2025.2520440.
7
Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.抗 CD19 单克隆抗体治疗复发或难治性 B 细胞恶性肿瘤：以弥漫性大 B 细胞淋巴瘤为重点的叙述性综述。
J Cancer Res Clin Oncol. 2022 Jan;148(1):177-190. doi: 10.1007/s00432-021-03833-x. Epub 2021 Nov 6.
8
Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.评估 loncastuximab tesirine 注射液治疗复发或难治性大 B 细胞淋巴瘤成人患者的疗效和安全性。
Expert Rev Anticancer Ther. 2021 Dec;21(12):1313-1320. doi: 10.1080/14737140.2021.1988853. Epub 2021 Oct 17.
9
Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma.洛卡妥昔单抗：一种治疗复发或难治性弥漫性大B细胞淋巴瘤的有效疗法。
Eur J Clin Pharmacol. 2022 May;78(5):707-719. doi: 10.1007/s00228-021-03253-3. Epub 2022 Jan 21.
10
Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States.在美国，在接受两种或更多线全身治疗后引入戈利木单抗治疗复发或难治性弥漫性大B细胞淋巴瘤的预算影响。
J Med Econ. 2025 Dec;28(1):595-604. doi: 10.1080/13696998.2025.2486839. Epub 2025 May 2.

本文引用的文献

1
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.接受epcoritamab或glofitamab治疗的侵袭性B细胞淋巴瘤患者的真实世界结局
Blood. 2025 Jul 15. doi: 10.1182/blood.2025029117.
2
Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.阿替利珠单抗、奥滨尤妥珠单抗和维奈克拉治疗复发/难治性B细胞非霍奇金淋巴瘤患者：来自LYSA组的一项II期试验的最终分析
Br J Haematol. 2025 Jul;207(1):110-122. doi: 10.1111/bjh.20109. Epub 2025 Apr 26.
3
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma.
静脉注射免疫球蛋白（IVIG）补充对接受靶向BCMA双特异性抗体治疗的多发性骨髓瘤患者无感染生存期的影响。
Blood Cancer J. 2025 Apr 23;15(1):74. doi: 10.1038/s41408-025-01282-0.
4
Atezolizumab consolidation in patients with high-risk diffuse large B-cell lymphoma in complete remission after R-CHOP.阿替利珠单抗用于经R-CHOP治疗后完全缓解的高危弥漫性大B细胞淋巴瘤患者的巩固治疗。
Blood Adv. 2025 Jul 22;9(14):3530-3539. doi: 10.1182/bloodadvances.2024015226.
5
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study.在CAR-T细胞治疗失败后，使用glofitamab治疗难治性或复发性弥漫性大B细胞淋巴瘤：一项2期LYSA研究。
Nat Cancer. 2025 Apr 3. doi: 10.1038/s43018-025-00941-2.
6
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.奥妥珠单抗单药治疗复发/难治性弥漫性大B细胞淋巴瘤患者：2期ELM-2试验的主要疗效和安全性分析
Nat Cancer. 2025 Mar;6(3):528-539. doi: 10.1038/s43018-025-00921-6. Epub 2025 Mar 17.
7
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial.埃普可妥单抗联合吉西他滨奥沙利铂治疗不适合移植的复发/难治性弥漫性大B细胞淋巴瘤：EPCORE NHL-2试验结果
Blood. 2025 Apr 10;145(15):1621-1631. doi: 10.1182/blood.2024026830.
8
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.在接受CAR T细胞治疗后进展的复发/难治性弥漫性大B细胞淋巴瘤中，odronextamab单药治疗：ELM-1研究的初步分析
Blood. 2025 Apr 3;145(14):1498-1509. doi: 10.1182/blood.2024027044.
9
Zanubrutinib plus R-CHOP for the treatment of newly diagnosed double-expressor lymphoma: A phase 2 clinical study.泽布替尼联合R-CHOP方案治疗新诊断的双表达淋巴瘤：一项2期临床研究。
Cancer. 2025 Jan 1;131(1):e35697. doi: 10.1002/cncr.35697.
10
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.格罗菲特单抗联合吉西他滨和奥沙利铂（GemOx）与利妥昔单抗-GemOx 治疗复发或难治性弥漫性大 B 细胞淋巴瘤（STARGLO）：一项全球性 3 期、随机、开放标签试验。
Lancet. 2024 Nov 16;404(10466):1940-1954. doi: 10.1016/S0140-6736(24)01774-4.